

WHO REPORT 2007


Global Tuberculosis Control

SURVEILLANCE, PLANNING, FINANCING



World Health
Organization

Warning: This report is out-of-date. In particular, entire time-series of TB disease burden estimates are updated every year. For the latest data and analysis, please see the most recent edition of the global TB report.



WHO REPORT 2007

Global Tuberculosis Control

SURVEILLANCE, PLANNING, FINANCING



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

World Health Organization

Global tuberculosis control : surveillance, planning, financing : WHO report 2007.

1.Tuberculosis, Pulmonary – prevention and control. 2.Tuberculosis, Multidrug-resistant – drug therapy. 3.Directly observed therapy. 4.Treatment outcome. 5.National health programmes – organization and administration. 6.Financing, Health. 7.Statistics.

I. Title

ISBN 92 4 156314 1

(NLM classification: WF 300)

WHO/HTM/TB/2007.376

Suggested citation:

Global tuberculosis control: surveillance, planning, financing. WHO report 2007. Geneva, World Health Organization (WHO/HTM/TB/2007.376)

© World Health Organization 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Cover: A primary aim of this report is to assess whether national TB control programmes reached the target of 70% case detection by the end of 2005. The coloured lines on the cover represent the increases in case detection in selected high-burden countries and regions between 1995 and 2005, based on data in Table 11. The countries that met the target are identified in the main text and annexes.

Designed by minimum graphics

Printed in Switzerland

Contents

Acknowledgements	v
Abbreviations	vi
Key points	1
Principales constataciones	3
Resultados principales	6
Introduction	9
Methods	10
Monitoring progress in TB control (1995–2005)	10
Goals, targets and indicators for TB control	10
Data collection and verification	10
High-burden countries, WHO regions and other subregions of the world	11
Implementation of DOTS and the Stop TB Strategy	11
DOTS coverage	12
Estimating TB incidence, prevalence and death rates	12
Case notification and case detection	13
Outcomes of treatment	15
Stop TB Strategy: implementation and planning (2005–2007)	16
Addressing TB/HIV, MDR-TB and other challenges	16
Financing the Stop TB Strategy (2002–2007)	17
Data collection	18
Data entry and analysis	18
GFATM contribution to TB control	20
Results	23
Monitoring progress in TB control	23
Countries reporting to WHO	23
Case notifications and incidence estimates	23
DOTS coverage	29
Case notification and case detection	29
Outcomes of treatment	33
Meeting targets for case detection and cure – results by country, region and worldwide	37
Progress towards the Millennium Development Goals	37
Stop TB Strategy: implementation and planning (2005–2007)	40
1. Pursue high-quality DOTS expansion and enhancement	40
2. Address TB/HIV, MDR-TB and other challenges	42
3. Contribute to health system strengthening	48
4. Engage all care providers	49
5. Empower people with TB, and communities	50
6. Enable and promote research	50
Financing TB control	50
Data received	50
NTP budgets and funding	51
Total cost of TB control	54
Budgets and costs per patient	57

	Expenditures compared with available funding and case detection	59
	GFATM contribution to TB control	60
Conclusions	Monitoring progress in TB control	63
	Case detection	63
	Outcomes of treatment	63
	Epidemiological trends and the impact of TB control	64
	Stop TB Strategy: implementation and planning	65
	Strategic planning	65
	Human resource development	65
	Quality-assured laboratory and treatment services	65
	Collaborative TB/HIV activities	65
	MDR-TB surveillance and control	66
	Strengthening health systems, improving access to care	67
	Working with people and communities	68
	Research to improve TB control	68
	Financing TB control	68
	National budgets compared with the Global Plan	68
	Financing the Global Plan	69
	Strengthening the financial monitoring system	70
Annex 1.	Profiles of high-burden countries	71
Annex 2.	The Stop TB Strategy, case reports, treatment outcomes and estimates of TB burden	161
	Explanatory notes	162
	Summary by WHO region	165
	Africa	171
	The Americas	187
	Eastern Mediterranean	203
	Europe	219
	South-East Asia	235
	Western Pacific	251
Annex 3.	Surveys of tuberculosis infection and disease, and death registrations, by country and year	267

Acknowledgements

The production of this report was coordinated by Christopher Dye, Katherine Floyd, Mehran Hosseini, Amy Piatek and Catherine Watt. The report was written by Christopher Dye, Katherine Floyd, Christian Gunneberg, Mehran Hosseini, Knut Lönnroth, Eva Nathanson, Andrea Pantoja, Amy Piatek, Mukund Uplekar, Catherine Watt, Brian Williams, Abigail Wright and Matteo Zignol.

The following WHO and UNAIDS staff assisted in compiling, analysing and editing information:

WHO HQ GENEVA AND UNAIDS: Mohamed Aziz, Pamela Baillie, Rachel Bauquerez, Karin Bergström, Léopold Blanc, Karen Ciceri, Giuliano Gargioni, Haileyesus Getahun, Andrea Godfrey, Eleanor Gouws, Kreena Govender, Malgorzata Grzemska, Ernesto Jaramillo, Knut Lönnroth, Rafael Lopez-Olarte, Doris Ma Fat, Dermot Maher, Fuad Mirzayev, Pierre-Yves Norval, Paul Nunn, Salah-Eddine Ottmani, Mario Raviglione, Krystyna Ryszewska, Fabio Scano, Tanya Siraa, Mukund Uplekar, Lana Velebit, Diana Weil.

WHO AFRICAN REGION: Stella Anyangwe (Zambia), Daniel Argaw (Ethiopia), Ayodele Awe (Nigeria), Oumou Bah-Sow (AFRO), Joseph Imoko (Uganda), Antoine Kabore (AFRO), Pierre Kahozi-Sanwa (Mozambique), Joel Kang-angi (Kenya), Samson Kefas (Nigeria), Bah Keita (AFRO, West Africa), Daniel Kibuga (AFRO), Mwendaweli Maboshe (Zambia), Motseng Makhetha (South Africa), Robert Makombe (AFRO), Giampaolo Mezzabotta (Uganda), Vainess Mfungwe (AFRO), Wilfred Nkhoma (AFRO), Angélica Salomão (Mozambique), Henriette Wembanyama (Democratic Republic of the Congo).

WHO REGION OF THE AMERICAS: Ademir Albuquerque (Brazil), Raimond Armengol (AMRO), Marlene Francis (CAREC), Albino Beletto (AMRO), Mirtha del Granado (AMRO), John Ehrenberg (AMRO), Xavier Leus (World Bank), Pilar Ramon-Pardo (AMRO), Rodolfo Rodriguez-Cruz (Brazil), Matías Villatoro (Brazil).

WHO EASTERN MEDITERRANEAN REGION: Aaiyad Al Dulaymi Munim (Somalia), Samiha Baghdadi (EMRO), Yuriko Egami (Pakistan), Sevil Husseinova (Afghanistan), Akihiro Seita (EMRO), Ireneaus Sindani (Sudan), Syed Karam Shah (Afghanistan).

WHO EUROPEAN REGION: Bakhtiyar Babamuradov (Uzbekistan), Cassandra Butu (Romania), Pierpaolo de Colombani (EURO), Irina Danilova (Russian Federation), Lucica Ditiu (EURO) Irina Dubrovina (Ukraine), Wieslaw Jakubowiak (Russian Federation), Olena Kheylo (Ukraine), Gudjon Magnusson (EURO), Konstantin Malakhov (Russian Federation), Kestutis Miskinis (Ukraine), Andrey Mosneaga (Caucasus), Dmitry Pashkevich (Russian Federation), Olena Radziyevska (South Caucasus), Igor Raykhert (Ukraine), Bogdana Scherbak-Verlan (Ukraine), Gombogaram Tsogt (Central Asia), Elena Yurasova (Russian Federation), Richard Zaleskis (EURO).

WHO SOUTH-EAST ASIA REGION: Mohammed Akhtar (Nepal), Marijke Becx-Bleumink (Bangladesh), Catherine Casalini (Myanmar), Kim Sung Chol (DPR Korea), Erwin Cooreman (SEARO), Puneet Dewan (SEARO), Hans Kluge (Myanmar), SS Lal (India), Petra Heitkamp (Indonesia), Franky Loprang (Indonesia), Firdosi Mehta (Indonesia), Nani Nair (SEARO), Myo Paing (Myanmar), Vason Pinyowiwat (DPR Korea), Suvanand Sahu (India), Chawalit Tantinimitkul (Thailand), Fraser Wares (India), Supriya Weerusavithana (Sri Lanka).

WHO WESTERN PACIFIC REGION: Tee Ah Sian (WPRO), Maarten Bosman (Viet Nam), Daniel Chin (China), Masami Fujita (Viet Nam), Philippe Glaziou (WPRO), Cornelia Hennig (China), Pratap Jayavanth (Cambodia), Wang Lixia (China), Pieter van Maaren (WPRO), Mauro Occhi (Fiji), Bernard Tomas (WPRO), Jamhoih Tonsing (WPRO), Michael Voniatis (Philippines), Rajendra Yadav (Papua New Guinea).

The primary aim of this report is to share information from national TB control programmes. The data presented here are supplied largely by the programme managers (listed in Annex 2) who have led the work on surveillance, planning and financing in countries. We thank all of them, and their staff, for their contributions. TB monitoring and evaluation at WHO are carried out with the financial backing of USAID. The WHO DOTS Expansion Project is supported by funding from the governments of Australia, Belgium, Canada, Germany, Ireland, the Netherlands, Norway, Switzerland, the United Kingdom and the United States of America. Data for the European Region were collected and validated jointly with EuroTB (Paris), a European TB surveillance network funded by the European Commission; we thank Dennis Falzon of EuroTB for his collaboration. We also thank designer Sue Hobbs for her habitual efficiency in helping to get this report published by 24 March, World TB Day.

Abbreviations

ACSM	Advocacy, communication and social mobilization	JICA	Japan International Cooperation Agency
AFB	Acid-fast bacilli	KAP	Knowledge, attitudes and practices
AFR	WHO African Region	LACEN	Brazilian public health laboratories
AFRO	WHO Regional Office for Africa	LGA	Local government area
AIDS	Acquired immunodeficiency syndrome	LHW	Lady health workers
AMR	WHO Region of the Americas	MDG	Millennium Development Goal
AMRO	WHO Regional Office for the Americas	MDR	Multidrug resistance (resistance to isoniazid and rifampicin)
ART	Antiretroviral therapy	MDR-TB	Multidrug-resistant tuberculosis
BPHS	Basic package of health-care services	MoH	Ministry of Health
CAREC	Caribbean Epidemiology Centre	NAP	National AIDS control programme or equivalent
CDC	Centers for Disease Control and Prevention	NGO	Nongovernmental organization
CHW	Community health worker	NRHM	National Rural Health Mission
CIDA	Canadian International Development Agency	NRL	National reference laboratory
CPT	Co-trimoxazole preventive therapy	NTP	National tuberculosis control programme or equivalent
CTBC	Community-based TB care	PAHO	Pan-American Health Organization
DoH	Department of Health	PAL	Practical Approach to Lung Health
DOT	Directly observed treatment	PATH	Program for Appropriate Technology in Health
DOTS	The internationally recommended strategy for TB control	PHC	Primary health care
DRS	Drug resistance surveillance or survey	PhilTIPS	Philippine Tuberculosis Initiatives for the Private Sector
DST	Drug susceptibility testing	PPM	Public-private or public-public mix
EMR	WHO Eastern Mediterranean Region	RIT/JATA	Research Institute of Tuberculosis, Japanese Anti-tuberculosis Association
EMRO	WHO Regional Office for the Eastern Mediterranean	SEAR	WHO South-East Asia Region
EQA	External quality assurance	SEARO	WHO Regional Office for South-East Asia
EUR	WHO European Region	SILTB	Brazilian laboratory information system
EURO	WHO Regional Office for Europe	SINAN	Brazilian health information system
FDC	Fixed-dose combination (or FDC anti-TB drug)	SWAp	Sector-wide approach
FIDELIS	Fund for Innovative DOTS Expansion, managed by IUATLD	TB	Tuberculosis
GDF	Global TB Drug Facility	TB CAP	Tuberculosis Control Assistance Program
GFATM	Global Fund to Fight AIDS, Tuberculosis and Malaria	UNAIDS	Joint United Nations Programme on HIV/AIDS
GLC	Green Light Committee	UNDP	United Nations Development Programme
Global Plan	<i>The Global Plan to Stop TB, 2006–2015</i>	UNHCR	United Nations High Commission for Refugees
GLRA	German Leprosy and TB Relief Association	the Union	International Union Against Tuberculosis and Lung Disease
GNI	Gross national income	USAID	United States Agency for International Development
GTZ	Deutsche Gesellschaft für Technische Zusammenarbeit (German society for technical co-operation)	VCT	Voluntary counselling and testing for HIV infection
HBC	High-burden country of which there are 22 that account for approximately 80% of all new TB cases arising each year	WHO	World Health Organization
HIV	Human immunodeficiency virus	WPR	WHO Western Pacific Region
HRD	Human resources development	WPRO	WHO Regional Office for the Western Pacific
ICDDR	International Centre for Diarrhoeal Diseases and Research	XDR-TB	TB due to MDR strains that are also resistant to a fluoroquinolone and at least one second-line injectable agent (amikacin, kanamycin and/or capreomycin)
IEC	Information, education, communication		
IHC	Integrated HIV Care (a programme of the Union)		
IPT	Isoniazid preventive therapy		
ISAC	Intensified support and action in countries, an emergency initiative to reach targets for DOTS implementation by 2005		

Key findings

The global TB epidemic

TB is still a major cause of death worldwide, but the global epidemic is on the threshold of decline

1. There were an estimated 8.8 million new TB cases in 2005, 7.4 million in Asia and sub-Saharan Africa. A total of 1.6 million people died of TB, including 195 000 patients infected with HIV.
2. TB prevalence and death rates have probably been falling globally for several years. In 2005, the TB incidence rate was stable or in decline in all six WHO regions, and had reached a peak worldwide. However, the total number of new TB cases was still rising slowly, because the case-load continued to grow in the African, Eastern Mediterranean and South-East Asia regions.

DOTS and the Stop TB Strategy

Most government health services now recognize that TB control must go beyond DOTS, but the broader Stop TB Strategy is not yet fully operational in most countries

3. More than 90 million TB patients were reported to WHO between 1980 and 2005; 26.5 million patients were notified by DOTS programmes between 1995 and 2005, and 10.8 million new smear-positive cases were registered for treatment by DOTS programmes between 1994 and 2004.
4. DOTS, which underpins the Stop TB Strategy, was being applied in 187 countries in 2005; 89% of the world's population lived in areas where DOTS had been implemented by public health services.
5. A total of 199 countries/areas reported 5 million episodes of TB in 2005 (new patients and relapses); 2.3 million new pulmonary smear-positive patients were reported by DOTS programmes in 2005, and 2.1 million were registered for treatment in 2004.
6. Skilled and highly-motivated staff are central to

8. Nearly 5 million TB patients were notified under DOTS in 2005, and the total number diagnosed and treated in 2006 is expected to be roughly in line with the Global Plan to Stop TB (2006–2015). However, smear-positive case detection rates by DOTS programmes varied among WHO regions in 2005, from 35% (Europe) to 76% (Western Pacific), and these variations are likely to persist into 2006.
9. The numbers of HIV-positive and multidrug-resistant TB (MDR-TB) patients diagnosed and treated in 2005, although increasing, were far lower than proposed in the Global Plan for 2006. HIV testing for TB patients is increasing quickly in the African Region, but little effort has yet been made to screen HIV-infected people for TB, though this is a relatively efficient method of case-finding. Facilities to diagnose and treat MDR-TB, including extensively drug-resistant TB (XDR-TB), are not yet widely available; the scale of the XDR-TB problem globally is not yet known.
10. The treatment success rate for MDR-TB patients in projects approved by the Green Light Committee (GLC) was close to 60%, and higher than in non-GLC projects.
11. The Stop TB Strategy is a mechanism for building links between NTPs, health-care providers and communities. The connections being made through community-based TB care, public-private mix DOTS and the Practical Approach to Lung Health have been shown, on a small to medium scale, to improve access to diagnosis and treatment. However, no country has yet succeeded in making all of these activities fully operational at national scale.
12. Few NTPs have an overview of TB research in their countries, and few have the skilled staff and funding needed to carry out essential operational research.

... the TB control

预览已结束，完整报告链接和二

<https://www.yunbaogao.cn/report/index/report?rep>